The Myth that the State can do Better: Medicaid Drug Prices and Managed Care Organizations

2021 ◽  
Author(s):  
Ike Brannon ◽  
Anthony T. Lo Sasso
Keyword(s):  
Managed Care ◽  
The State ◽  
Drug Prices ◽  
Managed Care Organizations

scholarly journals Treating depression in staff-model versus network-model managed care organizations

1999 ◽  
Vol 14 (1) ◽  
pp. 39-48 ◽  
Author(s):  
Lisa S. Meredith ◽  
Lisa V. Rubenstein ◽  
Kathryn Rost ◽  
Daniel E. Ford ◽  
Nancy Gordon ◽  
...  
Keyword(s):  
Managed Care ◽  
Network Model ◽  
Model Versus ◽  
Managed Care Organizations

The state and consequences of dermatology drug prices in the United States

2016 ◽  
Vol 75 (3) ◽  
pp. 603-605 ◽  
Author(s):  
Joerg Albrecht ◽  
Mark Lebwohl ◽  
Maryam M. Asgari ◽  
Daniel D. Bennett ◽  
Ashley Cook ◽  
...  
Keyword(s):  
United States ◽  
The United States ◽  
The State ◽  
Drug Prices

Cost of atrial fibrillation in United States managed care organizations

2009 ◽  
Vol 26 (9) ◽  
pp. 847-857 ◽  
Author(s):  
Michael H. Kim ◽  
Jay Lin ◽  
Mohamed Hussein ◽  
Charles Kreilick ◽  
David Battleman
Keyword(s):  
United States ◽  
Atrial Fibrillation ◽  
Managed Care ◽  
Managed Care Organizations

Managed Care Organizations' Assessment of Reimbursement for New Technology, Procedures, and Drugs

1999 ◽  
Vol 123 (8) ◽  
pp. 677-679
Author(s):  
Harold Zarkowsky
Keyword(s):  
Managed Care ◽  
New Technology ◽  
Third Party ◽  
Medical Community ◽  
Extensive Literature ◽  
Behavioral Measures ◽  
Randomized Controlled Studies ◽  
Marginal Improvement ◽  
Managed Care Organizations

Abstract Managed care organizations must establish formal processes for the evaluation of new technology, procedures, and drugs to enhance the quality of health care delivered and to support coverage and utilization decision making. Evidence-based research and the results of controlled clinical trials are the preferred sources of outcomes data to support the safety and effectiveness of the technology, procedure, or drug under review. In addition to extensive literature review, the opinion of experts in the field and acceptance by the medical community are considered. Assessments of new technology and drugs are available for purchase from several vendors, and managed care organizations can adopt or modify such evaluations to develop medical coverage policies. The research community can assist third-party payers by conducting studies on practices that might lead to substantial, rather than marginal, improvement in health, pay particular attention to study design when randomized controlled studies are not possible, and include functional and behavioral measures in analysis of outcomes.

Sign in / Sign up

Export Citation Format

Share Document